Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

MedReleaf reports Q2 2018 financial results. Total grams sold increases by 23% vs. YA

MedReleaf reports Q2 2018 financial results. Total grams sold increases by 23% vs. YAMarkham, Ontario-based medical cannabis producer MedReleaf (TSX: LEAF) reported results for Q2 2018 ending September 30. Sales volume increased to 1.05 million grams, a 23% increase from same period year ago (YAG).

Revenue figures were lower versus YAG, as expected, due to reductions in the past year by the Veterans Affairs Policy (VAC) in the price and volume of cannabis for which veterans can be reimbursed. The VAC rule now stipulates veterans can be reimbursed for a maximum of 3 grams per day at a price of $8.50 per gram.

As a result, MedReleaf’s price per gram dropped from $12.29 in Q2 2016, to $9.34 in recent Q2 2018. This caused its total revenue to decrease 9% to $9.8 million, despite an increase of 23% in grams sold.

MedReleaf is still the second largest cannabis producer by revenue, second only to Canopy Growth in North America. It is 5th largest by market cap with $1.24 billion CAD.

Management noted that financial results versus year ago will improve as the VAC changes fall further in the past and are no longer captured in year over year stats.

In other news, the company recently announced it will launch MedReleafRx in January 2018. This is the first genetic test, administered as a cheek swab, that will enable physicians to determine a patient’s relative rate of cannabis absorption, making doctors’ dosage prescriptions more accurate.

MedReleaf has increased production capacity by 80% since April 2017.

Source: MedReleaf press release

MedReleaf reports Q2 2018 financial results. Total grams sold increases by 23% vs. YA

About Cannin Investment Group: Your Pot Stocks Experts

Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020. 

Use Cannin as your resource for:

Is it too late to invest in pot stocks? No! This is the perfect time to invest.

Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.

Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?

Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • 108% Backtested since 2012

We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best pot stocks – we’ll show you how at

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks to Invest In